Combination therapy for relapsed B-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a B-cell blood cancer that returned or did not respond to treatment.
- You must be 18 or over and able to give written consent.
- Your cancer must have measurable signs on tests.
- You should be generally active and able to care for yourself (ECOG 0-2).
- Your organs (like liver, kidneys) must work well enough for treatment.
- You must agree to use highly effective birth control or abstain from donating eggs or sperm during and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill, tacabrutideg, for blood cancers that have returned or not improved after earlier treatments. It may work for patients who have already tried a type of targeted therapy called a BTK inhibitor.
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This study tests a new combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—in people with large B-cell lymphoma that has come back or not responded to earlier treatment. The goal is to see if this combination can shrink or control the lymphoma.
This study tests a new combination of drugs for people with aggressive B-cell lymphoma that has not gotten better or has come back. The goal is to see if the combination helps control the cancer.
Hear when a new Relapsed Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.